NCT01491087View on ClinicalTrials.gov

Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China

PHASE4CompletedINTERVENTIONAL

Enrollment

900

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

December 31, 2012

Conditions

DiphtheriaTetanusPertussisPolio

Interventions

BIOLOGICAL

DTacP IPV//PRP~T combined vaccine: PENTAXIM®

0.5 mL, Intramuscular

Trial Locations (3)

200336

Shanghai

300011

Tianjin

510300

Guangzhou

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01491087 - Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China | Biotech Hunter | Biotech Hunter